HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM

The primary objectives of this study are to determine the safety of single agent Selinexor given with commercial bispecific antibody therapy in patients with Relapsed/Refractory Multiple Myeloma (RRMM) and to determine the MRD negativity rate at 10-5 at 12 months post bispecific antibody therapy. The investigators will enroll 27 patients with RRMM who are receiving commercial bispecific antibody therapy. Patients will be on treatment for 12 months or until disease progression, and will be followed for 24 months. Study assessments include completing a drug diary, having a safety check in call,

Trial Details

NCT ID
NCT06822972
Phase
PHASE2
Sponsor
Duke University
Status
RECRUITING
Cancer Type
Multiple Myeloma
Interventions
  • Selinexor 40 mg
Locations (sample)
  • Durham, North Carolina, United States|35.99403,-78.89862

Key Eligibility Criteria

  • Age ≥ 18 years old at the time of informed consent.
  • Willing and able to provide written informed consent in accordance with federal, local, and institutional guidelines. The patient must provide info…
  • Eastern Cooperative Oncology Group (ECOG) performance status of ≤2
  • A diagnosis of symptomatic multiple myeloma, with relapsed or refractory disease. Patients must have received at least 4 prior lines of therapy. Pr…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →